Advertisement

Inpharma Weekly

, Volume 971, Issue 1, pp 13–14 | Cite as

TB or not TB? - Rifater® may be the answer

  • Jo Barnes
Newsletter Article

&

Tuberculosis is once again top of the list of killer infectious diseases in adults throughout the world. Of particular concern is the rise in the incidence of multidrug-resistant strains of Mycobacterium tuberculosis

One approach to reducing the development of multidrug-resistant TB may lie in improving patient compliance. In answer to this, Marion Merrell Dow has recently launched Rifater® in the US, the only triple combination therapy for the treatment of active TB.

Keywords

Rifampicin Isoniazid Pyrazinamide Rifamycin Improve Patient Compliance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Jo Barnes

There are no affiliations available

Personalised recommendations